Executive Viability Abstract
This study assesses the feasibility of developing a nation-wide Digital Health Innovation Infrastructure (DHII) in Switzerland. Leveraging Switzerland's position as a global biotech hub and its high healthcare expenditure (11.8% of GDP), the project focuses on interoperable data exchange, AI-driven diagnostics, and personalized medicine platforms. The analysis indicates high financial viability driven by clinical efficiency gains and the shift toward value-based care.
Return on Investment
145%
Payback Span
4.2 years
Net Present Value
CHF 45,500,000
IRR Index
22.4%
## Market Analysis
Switzerland represents one of the most sophisticated healthcare markets globally. The digital health sector is projected to grow at a CAGR of 12.5% through 2030. Key drivers include the Electronic Patient Record (EPR) mandates and a high density of pharmaceutical players (Novartis, Roche) requiring real-world evidence (RWE) data. Competitors are fragmented, leaving room for a unified infrastructure provider.
## Technical Feasibility
The project will utilize FHIR-based API architectures and blockchain for secure patient consent management. Switzerland's strict data privacy laws (FADP) and alignment with GDPR require local data residency. Technical risk is mitigated by the presence of Tier-IV data centers and world-class engineering talent from ETH Zurich and EPFL.
## Financial Projections
Total Addressable Market (TAM) for Swiss healthtech infrastructure is estimated at CHF 1.2B. The project targets 15% market share by year 5. Capex is front-loaded for platform development and hospital integration, while revenue is recurring through SaaS and data-as-a-service models.
## Risk Assessment
Primary risks include slow adoption of EPR by cantonal hospitals and regulatory shifts. Mitigation involves deep integration with existing HIS (Hospital Information Systems) and proactive compliance with the Swiss Personal Data Protection Act.